Latest news
Sobi, Innate sign $580M pact to propel lymphoma drug through Phase III - FirstWord PharmaFirstWord Pharma · Mon, 10 Aug 2026 15:22:30 GMTSobi licenses lacutamab from Innate Pharma - The Pharma LetterThe Pharma Letter · Mon, 10 Aug 2026 15:11:15 GMTM&A Roundup: Novo Nordisk Enters AI Drug Discovery Partnership with Amazon, Innate Pharma Partners with Sobi, Innovent Enters Commercialization Agreement with Daiichi Sankyo - pharmexec.compharmexec.com · Mon, 10 Aug 2026 13:53:58 GMTSobi pens $580M deal for Innate’s cancer drug before ph. 3 push - Fierce BiotechFierce Biotech · Mon, 10 Aug 2026 11:13:48 GMTInnate Pharma (NASDAQ: IPHA) secures Sobi deal, $75M upfront and Phase 3 push - Stock TitanStock Titan · Mon, 10 Aug 2026 10:05:10 GMTInnate Pharma advances lacutamab to Phase 3 and appoints CMO - World Business OutlookWorld Business Outlook · Mon, 10 Aug 2026 09:40:28 GMTAlmirall partners with CrystalO for dermatology drug discovery - World Business OutlookWorld Business Outlook · Mon, 10 Aug 2026 09:40:28 GMTInnate Pharma Secures Funding and Advances Lacutamab to Phase 3 With New CMO - TipRanksTipRanks · Mon, 10 Aug 2026 07:56:43 GMT